Advertisement
Advertisement
U.S. Markets open in 4 hrs 47 mins
Advertisement
Advertisement
Advertisement
Advertisement

Neoleukin Therapeutics, Inc. (NLTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.0200-0.0200 (-1.92%)
At close: 04:00PM EDT
0.9800 -0.04 (-3.92%)
After hours: 06:57PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0400
Open1.0500
Bid0.0000 x 1000
Ask0.0000 x 900
Day's Range0.9800 - 1.0700
52 Week Range0.7950 - 9.7500
Volume172,414
Avg. Volume380,535
Market Cap43.277M
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-1.0590
Earnings DateMar 23, 2022 - Mar 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.71
  • GlobeNewswire

    Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)

    SEATTLE, May 16, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced treatment of the first patient in a combination arm evaluating the safety and efficacy of Neoleukin’s NL-201 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), as part of Neoleukin’s ongoing Phase 1 trial in patients with relapsed or refractory soli

  • GlobeNewswire

    Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update

    SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the quarter ending March 31, 2022 and provided a corporate update. “During the first quarter of 2022 our dedicated team at Neoleukin has been focused on execution of our NL-201 Phase 1 clinical trial, evaluating multiple schedules during dose escala

  • GlobeNewswire

    Neoleukin Therapeutics to Present at Upcoming Investor Conferences

    SEATTLE, May 05, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in two upcoming investor conferences. Presentation details are as follows: BofA Securities 2022 Healthcare Conference – Las Vegas, NV Fireside chatWednesday May 11, 2022, at 1:20 p.m. Pacific H.C. Wa

Advertisement
Advertisement